ATLANTA, GA — March 18, 2002 — Prophylactic use of acetylcysteine prevents reduction of renal function after coronary angiography, according to results reported here at the 51st Annual Scientific Session of the American College of Cardiology (ACC).
Researchers from the Geisinger Medical Center in Danville, Pennsylvania, also demonstrated that the benefit was greater in patients with baseline serum creatinine levels that were 2 mg/dL or greater.
Transient renal insufficiency after exposure to radiocontrast agents has been well described, and the only preventive measure that has been validated in the setting of coronary angiography is pre- and post-procedure hydration, Dr. Elie Mouhayar explained.
Acetylcysteine has been shown to have clinical benefit in preventing radiocontrast-induced nephropathy if administered orally for 24 hours before and after computed tomography scan studies. Patients undergoing cardiac catheterization receive on average a higher volume of contrast agent and have variable hemodynamic conditions, he said. Accordingly, his group studied the potential benefit of oral acetylcysteine in preventing renal dysfunction in patients undergoing cardiac catheterization.
Fifty-five consecutive patients receiving three doses of acetylcysteine prior to cardiac catheterization were compared to 55 historical controls. All patients in both groups had a baseline serum creatinine level of 1.2 mg/dL or greater and received intravenous hydration before and after the procedure. Serum creatinine levels at baseline and 48 hours after the procedure were compared.
Changes in creatinine mean values after 48 hours were -0.4 (±0.3) and +0.1 (±0.3) mg/dL for treatment and control groups, respectively (p<0.001). The benefit was larger in patients with baseline creatinine levels higher than 2 mg/dL, at -0.4 (±0.4) compared to +0.5 (±0.3) mg/dL (p<0.001).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!